Legal Proceedings	3 Months Ended
Mar. 29, 2025
Legal Proceedings [Abstract]
Legal Proceedings	Note 11 – Legal Proceedings Henry Schein, Inc. has been named as a defendant in multiple opioid related lawsuits (currently less than one- hundred ( 100 ); one or more of Henry Schein, Inc.’s subsidiaries is also named as a defendant in a number of those cases). Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and its subsidiaries) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. These actions consist of some that have been consolidated within the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently stayed, and others which remain pending in state courts and are proceeding independently and outside of the MDL. On March 19, 2025, the court granted our motion to dismiss the purported class action filed by San Miguel Hospital Corporation d/b/a Alta Vista Regional Hospital, et al. in the United States District Court for the District of New Mexico and dismissed all claims against Henry Schein with prejudice. Plaintiff has filed a motion to amend the judgment and for leave to file a second amended complaint, which is pending. Twenty other cases filed by legal guardians of children who were allegedly exposed to opioids in utero have been voluntarily dismissed. At this time, the following case is set for trial: the action filed by Florida Health Sciences Center, Inc. (and 25 other hospitals located throughout the State of Florida) in Florida state court, which is currently scheduled for a jury trial in September 2025. Of Henry Schein’s 2024 net sales of approximately $ 12.7 billion, sales of opioids represented less than four -tenths of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions. From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations. As of March 29, 2025, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Henry Schein, Inc. has been named as a defendant in multiple opioid

related lawsuits (currently less than one-

hundred (

100

); one or more of Henry Schein, Inc.’s subsidiaries is also named as a defendant in a number of

those

cases).

Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false

advertising campaign to expand the market for such drugs and their own

market share and that the entities in the

supply chain (including Henry Schein, Inc. and its subsidiaries) reaped

financial rewards by refusing or otherwise

failing to monitor appropriately and restrict the improper distribution of those

drugs.

These actions consist of some

that have been consolidated within the MultiDistrict Litigation (“MDL”)

proceeding In Re National Prescription

Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently

stayed, and others which remain

pending in state courts and are proceeding independently and outside of

the MDL.

On March 19, 2025, the court

granted our motion to dismiss the purported class action filed by San

Miguel Hospital Corporation d/b/a Alta Vista

Regional Hospital,

et al. in the United States District Court for the District of New

Mexico and dismissed all claims

against Henry Schein with prejudice.

Plaintiff has filed a motion to amend the judgment and for leave to file

second amended complaint, which is pending.

Twenty

other cases filed by legal guardians of children who were

allegedly exposed to opioids in utero have been voluntarily dismissed.

At this time, the following case is set for

trial: the action filed by Florida Health Sciences Center, Inc. (and

other hospitals located throughout the State of

Florida) in Florida state court, which is currently scheduled

for a jury trial in September 2025.

Of Henry Schein’s

2024 net sales of approximately $

12.7

billion, sales of opioids represented less than

four

-tenths of 1

percent.

Opioids represent a negligible part of our business.

We intend to defend ourselves vigorously against

these actions.

From time to time, we may become a party to other legal proceedings,

including, without limitation, product

liability claims, employment matters, commercial disputes, governmental

inquiries and investigations (which may

in some cases involve our entering into settlement arrangements or consent

decrees), and other matters arising out

of the ordinary course of our business.

While the results of any legal proceeding cannot be predicted with certainty,

in our opinion none of these other pending matters are currently

anticipated to have a material adverse effect on our

consolidated financial position, liquidity or results of operations.

As of March 29, 2025,

we had accrued our best estimate of potential losses relating

to claims that were probable to

result in liability and for which we were able to reasonably estimate a

loss.

This accrued amount, as well as related

expenses, was not material to our financial position, results of operations

or cash flows.

Our method for

determining estimated losses considers currently available

facts, presently enacted laws and regulations and other

factors, including probable recoveries from third parties.